Rebecca Canter

Rebecca Canter is an Associate at SV Health Investors, a global healthcare-focused private equity and venture capital firm operating out of its Boston and London offices. In her role, she supports a specialist fund manager that has built a portfolio of more than 200 companies over three decades of operation. The firm's historical investments have contributed to the development of 20 novel drug licenses and six new drug classes across the medical technology and biotechnology sectors. Canter's organization actively deploys capital from pre-seed through Series C stages, participating in recent notable transactions such as a $68.0 million Series B round for NRG Therapeutics and a $32.0 million Series A for Alchemab Therapeutics. With exposure to additional portfolio companies like CarePredict and Quanta Therapeutics, her current focus centers on evaluating and scaling innovative therapeutic and dementia research enterprises.